ResearcherSheba Medical CenterNo recent work listed

Abraham Czerniak

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5003513593. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2012: 2 papers

Papers 2

Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable panc… Co-author DOI 10.1038/cgt.2012.10 ↗
H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. Last author DOI 10.5402/2012/351750 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Avraham Hochberg · 2 shared papers, 2012 · strength 0.06
- Paper Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of B… DOI 10.1038/cgt.2012.10 ↗
- Paper H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. DOI 10.5402/2012/351750 ↗
Ayala Hubert · 2 shared papers, 2012 · strength 0.06
- Paper Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of B… DOI 10.1038/cgt.2012.10 ↗
- Paper H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. DOI 10.5402/2012/351750 ↗
Fred Meir Konikoff · 1 shared paper, 2012 · strength 0.03
- Paper Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of B… DOI 10.1038/cgt.2012.10 ↗
Nader N Hanna · 1 shared paper, 2012 · strength 0.03
- Paper Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of B… DOI 10.1038/cgt.2012.10 ↗
Vladimir Sorin · 1 shared paper, 2012 · strength 0.03
- Paper H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. DOI 10.5402/2012/351750 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.